This new treatment could help French bulldogs breathe easier

Updated May 1, 2026, 5:18 p.m. ETFlat-faced dog breeds like French bulldogs are at high risk for a serious breathing condition called BOAS.Australian researchers are testing a new injectable therapy, Snoretox-1, as a less invasive alternative to surgery.The new treatment uses a modified tetanus toxin to strengthen throat muscles and open the dog's airway.Snoretox-1 is still in early trials but may become available in the U.S. after further studies and FDA approval.French bulldogs are one of America’s most popular dog breeds. But their signature flat faces can come with serious breathing risks, such as brachycephalic obstructive airway syndrome (BOAS). If left untreated, bulldogs and similar breeds can struggle with physical activity, experience sleep disruptions, and have a shorter life expectancy.Surgery is currently the standard treatment for BOAS, but another option may soon be available. Australian researchers are currently testing a new injectable therapy, Snoretox-1, that may provide a safer alternative. Why do flat-faced dogs face breathing difficulties?BOAS is a serious respiratory condition caused by anatomical abnormalities, including nasal airway narrowing and a long soft palate. It can cause symptoms like breathing difficulties, snoring, easy overheating, exercise intolerance and, in some cases, collapse.Treatment is important because severe BOAS can shorten a